The prevalence of arterial hypertension is very high all over the world. ~0.1% of subjects with secondary hypertension has a pheochromocytoma, a tumor producing catecholamines. The quantification of free plasma o-methylated metabolites, metanephrine (p-MN) and normetanephrine (p-NMN), is considered the most accurate test for both the diagnosis and monitoring of pheochromocytoma. The aim of this work was to validate of an assay for measuring plasma metanephrines by LC-MS/MS. Calibration curves showed good linearity (R2 >0.99). Intra-Assay repeatibility, assessed on two pools, normal and pathological, resulted in a CV of 5.1% and 3.9% for p-MN and 8.2% and 10.5% for p-NMN, respectively. Inter-Assay CVs were 15.9% and 11.9% for p-MN and 16.6% and 16.1% for p-NMN, respectively. The limit of detection was 8 pM for p-MN and 66 pM for p-MNM, while the limit of quantification was 26 pM for p-MN and 83 pM for p-NMN. 638 plasma samples were analyzed, providing a representative sample to assess potential clinical impact of the validated method.

Validation of the measurement of plasma metanephrines by liquid chromatography-Tandem mass spectrometry (LC-MS/MS)

Nonnato A.;Incardona S.;Mengozzi G.
2017-01-01

Abstract

The prevalence of arterial hypertension is very high all over the world. ~0.1% of subjects with secondary hypertension has a pheochromocytoma, a tumor producing catecholamines. The quantification of free plasma o-methylated metabolites, metanephrine (p-MN) and normetanephrine (p-NMN), is considered the most accurate test for both the diagnosis and monitoring of pheochromocytoma. The aim of this work was to validate of an assay for measuring plasma metanephrines by LC-MS/MS. Calibration curves showed good linearity (R2 >0.99). Intra-Assay repeatibility, assessed on two pools, normal and pathological, resulted in a CV of 5.1% and 3.9% for p-MN and 8.2% and 10.5% for p-NMN, respectively. Inter-Assay CVs were 15.9% and 11.9% for p-MN and 16.6% and 16.1% for p-NMN, respectively. The limit of detection was 8 pM for p-MN and 66 pM for p-MNM, while the limit of quantification was 26 pM for p-MN and 83 pM for p-NMN. 638 plasma samples were analyzed, providing a representative sample to assess potential clinical impact of the validated method.
2017
41
1
50
59
Lucchiari M.; Nonnato A.; Vitale A.R.; Incardona S.; Martinelli F.; Vitali S.; Mengozzi G.
File in questo prodotto:
File Dimensione Formato  
1306-050-059_lucchiari.pdf

Accesso aperto

Dimensione 305.24 kB
Formato Adobe PDF
305.24 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1890021
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact